Prime Medicine Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Prime Medicine Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PRME
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001894562
Board of directors
-
Allan Reine · Director · Chief Executive OfficerSince 2025
-
David P. Schenkein · DirectorSince 2023
-
Jeffrey D. Marrazzo · DirectorSince 2023
-
Kaye I. Foster-Cheek · DirectorSince 2023
-
Keith Michael Gottesdiener · Director · See RemarksSince 2023
-
Michael Aaron Kelly · DirectorSince 2023
- Since 2023
-
Thomas Cahill · DirectorSince 2023
-
Wendy Chung · DirectorSince 2023
Chief executives
Allan Reine
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 5, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
79.5%
-
97.2%
Board connections
6 of this board's directors also sit on 11 other boards.
- via David P. Schenkein and Kaye I. Foster-Cheek
- via Michael Aaron Kelly
- via David P. Schenkein
- via Robert Nelsen
- via Robert Nelsen
- via Michael Aaron Kelly
- via Wendy Chung
- via David P. Schenkein
- via Robert Nelsen
- via Keith Michael Gottesdiener
- via Robert Nelsen
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 1, 2025 | Alphabet Inc. 10% owner | Open-market purchase | +1,500,000 | $3.30 | $4,950,000 |
| Aug 1, 2025 | Robert Nelsen Director, 10% owner | Open-market purchase | +3,030,300 | $3.30 | $9,999,990 |
| Aug 1, 2025 | ARCH Venture Fund XII, L.P. 10% owner | Open-market purchase | +3,030,300 | $3.30 | $9,999,990 |
| Aug 1, 2025 | Steven Gillis 10% owner | Open-market purchase | +3,030,300 | $3.30 | $9,999,990 |
| Jun 30, 2025 | Liu David R. 10% owner | Open-market purchase | +21,000 | $2.52 | $52,920 |
| Jun 23, 2025 | Liu David R. 10% owner | Open-market purchase | +21,000 | $2.16 | $45,360 |
| Jun 16, 2025 | Liu David R. 10% owner | Open-market purchase | +21,000 | $1.49 | $31,290 |
| Jun 11, 2025 | Liu David R. 10% owner | Open-market purchase | +21,000 | $1.60 | $33,600 |
| May 21, 2025 | LEE ANN L. Officer (Chief Technical Officer) | Open-market purchase | +100,000 | $1.13 | $113,000 |
| May 21, 2025 | Allan Reine Director, Officer (Chief Executive Officer) | Open-market purchase | +125,000 | $1.18 | $147,500 |
| May 20, 2025 | Richard Brudnick Officer (Chief Business Officer) | Open-market purchase | +20,000 | $1.19 | $23,800 |
| Oct 8, 2024 | Keith Michael Gottesdiener Director, Officer (See Remarks) | Gift | −226,925 | — | — |
| Oct 8, 2024 | Keith Michael Gottesdiener Director, Officer (See Remarks) | Gift | +226,925 | — | — |
| Jun 5, 2024 | Keith Michael Gottesdiener Director, Officer (See Remarks) | Gift | −250,000 | — | — |
| Jun 5, 2024 | Keith Michael Gottesdiener Director, Officer (See Remarks) | Gift | +250,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.